涉及跨膜区的CD74/SLC34A2-ROS1融合变体独立于TP53突变预测非小细胞肺癌对克唑替尼的不良反应
本研究通过DNA/RNA二代测序和免疫组化分析210例ROS1融合非小细胞肺癌,发现长型ROS1融合(外显子32)较短路型(外显子34/35)一线克唑替尼中位无进展生存期更短(8.0个月对24.0个月,p=0.006),长型CD74/SLC34A2-ROS1融合独立于TP53突变与更短无进展生存期相关。
要点
- 长型ROS1融合(外显子32)患者一线克唑替尼中位无进展生存期8.0个月,短型为24.0个月(p=0.006)。
- 长型CD74/SLC34A2-ROS1融合患者无进展生存期短于其他ROS1融合,独立于TP53突变状态。
- BIM缺失多态性患者中位无进展生存期5.0个月,无BIM缺失者为22.0个月(p=0.003)。
核心结论
- 长型CD74/SLC34A2-ROS1融合保留ROS1及融合伴侣的跨膜区,与克唑替尼不良疗效相关,且独立于TP53突变。
研究设计与样本
- 采用DNA和RNA二代测序及免疫组化鉴定ROS1融合,共纳入210例ROS1融合非小细胞肺癌病例,其中常见融合171例、少见融合39例。
主要发现
- DNA二代测序在常见ROS1融合中检测到不同的ROS1基因组断点,RNA二代测序发现ROS1断点主要位于外显子32、34和35,分别导致长型(外显子32)和短型(外显子34或35)ROS1融合。
- ROS1免疫组化显示长型ROS1融合以膜性和胞质性染色为主,短型以胞质性染色为主(p=0.006)。
- 一线克唑替尼患者中,长型ROS1融合中位无进展生存期8.0个月,短型为24.0个月(p=0.006)。
- TP53突变患者与无TP53突变患者中位无进展生存期分别为8.0个月和19.0个月(p=0.159)。
- BIM缺失多态性患者与无BIM缺失多态性患者中位无进展生存期分别为5.0个月和22.0个月(p=0.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Variable partners and breakpoints have been reported in patients with ROS1-rearranged NSCLC. Here, we investigated the association of fusion partners and breakpoints with crizotinib efficacy in NSCLCs with common ROS1 fusions. METHODS: DNA and RNA next-generation sequencing (NGS) and immunohistochemistry were performed to characterize ROS1 fusions. RESULTS: Using DNA NGS, we identified ROS1 fusions in 210 cases, comprising 171 common (CD74/EZR/TPM3/SDC4/SLC34A2-ROS1) and 39 uncommon (variants identified in <5%) ROS1 fusion cases. DNA NGS detected variable ROS1 genomic breakpoints in common ROS1 fusions, whereas RNA NGS found ROS1 breakpoints mainly occurring in exons 32, 34 and 35, resulting in long (exon 32) and short (exon 34 or 35) ROS1 fusions. ROS1 immunohistochemistry revealed that membranous and cytoplasmic staining was predominant in long ROS1 fusions, whereas cytoplasmic staining was predominant in short ROS1 fusions (p = 0.006). For patients who received first-line crizotinib, median progression-free survival (mPFS) was lower in patients with long ROS1 fusions than those with short ROS1 fusions (8.0 versus 24.0 mo, p = 0.006). Moreover, mPFS for patients with and without TP53 mutations was 8.0 and 19.0 months, respectively (p = 0.159); mPFS for patients with and without BIM deletion polymorphism was 5.0 and 22.0 months, respectively (p = 0.003). When analyzing together with fusion partners, patients with long CD74/SLC34A2-ROS1 fusions were found to have shorter PFS than those with other ROS1, regardless of the presence or absence of TP53 mutations (p < 0.001 and p = 0.002, respectively). CONCLUSIONS: Long CD74/SLC34A2-ROS1 fusions, which retain transmembrane regions in ROS1 and fusion partners, are associated with poor response to crizotinib independent of TP53 mutations.
引用
- Li W, Fei K, Guo L, et al. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations. J Thorac Oncol. 2023. PMID: 38070598. doi:10.1016/j.jtho.2023.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。